For this period, Protagonist Therapeutics reports a gross margin of 99.8%, an operating margin of 58.6%, an EBITDA margin of 64.1%, and a net margin of 62%. Operating margin recorded the largest year-over-year gain at 49.5 percentage points, whereas gross margin recorded the largest decline at 0.2 percentage points.
Protagonist Therapeutics's margins averaged 99.98% gross, -31.66% operating, -12.45% EBITDA, and -15.27% net over the last 3 years. The current figures show operating, EBITDA, and net margins are above their three-year averages, while gross margin is below its three-year average.
Protagonist Therapeutics's operating margin expanded by 49.5 percentage points, EBITDA margin by 39.8 percentage points, and net margin by 40.1 percentage points, but gross margin contracted by 0.2 percentage points.
Protagonist Therapeutics recorded an average gross margin of 99.98% across the last 3 years. Against its three-year average, Protagonist Therapeutics's gross margin is currently 99.8%, 0.2 percentage points below its three-year average. Looking back over the last 3 years, Protagonist Therapeutics's gross margin reached 100% at its highest point in Jun 2026 and 99.8% at its lowest in Sep 2026.
Over the last 3 years, Protagonist Therapeutics's operating margin averaged -31.66%. At present, Protagonist Therapeutics's current operating margin is 58.6%, which is 90.3 percentage points above its three-year average. During this period, operating margin reached a high of 58.6% in Sep 2026 and a low of -343.6% in Dec 2025.
Protagonist Therapeutics's EBITDA margin averaged -12.45% across the past 3 years. Compared with its three-year average, Protagonist Therapeutics's current EBITDA margin is 64.1% and is 76.6 percentage points above its three-year average. Over the last 3 years, Protagonist Therapeutics's EBITDA margin peaked at 65% in Dec 2024 and reached a low of -274.8% in Dec 2025.
Protagonist Therapeutics's net margin averaged -15.27% during the last 3 years. Compared with its three-year average, Protagonist Therapeutics's current net margin is 62% and is 77.3 percentage points above its three-year average. Over the last 3 years, Protagonist Therapeutics's net margin peaked at 63.3% in Dec 2024 and reached a low of -282.8% in Dec 2025.
Protagonist Therapeutics's gross margin of 99.8% is above the Healthcare sector and the industry average. Compared to its Healthcare sector average of 68.6%, Protagonist Therapeutics's gross margin is 45% higher.
As of Sep 30, 2026, PTGX has a gross margin of 99.8%.
As of Sep 30, 2026, PTGX has an operating margin of 58.6%.
As of Sep 30, 2026, PTGX has an EBITDA margin of 64.1%.
As of Sep 30, 2026, PTGX has a net margin of 62%.
Over the past 3 years, PTGX reported average margins of 100.0% gross, -31.7% operating, -12.5% EBITDA, and -15.3% net.
Looking back across 5 years, PTGX reached 100% gross in Jun 2026, 58.6% operating in Sep 2026, 65% EBITDA in Dec 2024, and 63.3% net in Dec 2024.
Within the 5-year period, PTGX recorded its lowest margins at 99.8% gross in Sep 2026, -17,029.5% operating in Mar 2023, -15,927.8% EBITDA in Mar 2023, and -16,319.9% net in Mar 2023.